Groundbreaking treatment targets glioblastoma with tumor-based cells
Nov. 4
Glioblastoma remains one of the most aggressive and lethal brain cancers, with few effective treatment options and an average survival of just over a year after diagnosis. Now, researchers at Banner MD Anderson have advanced to Phase II of a groundbreaking clinical trial using personalized immunotherapy made from patients’ own tumor cells. The approach is aimed at training the immune system to recognize and fight each unique cancer. Dr. Ramya Tadipatri and Dr. Joseph Georges joined “Arizona Horizon” to share how this experimental therapy works and what early results mean for patients and families.
In this segment:
Also in this episode:
SPOTLIGHT
STAY in touch
with azpbs.org!
Subscribe to Arizona PBS Newsletters:
